Mundipharma expands Santen partnership

Mundipharma has expanded a partnership with Santen Pharmaceutical, according to a press release.

The extension of an existing license for Saflutan (tafluprost) will add approximately 50 Middle Eastern and African markets.

In addition, the company will add Taptiqom (tafluprost/timolol) to its license in Canada, Australia, New Zealand, Latin America, the Middle East and Africa.

“We are delighted to further expand our ophthalmic portfolio as well as our successful partnership with Santen, ” Raman Singh, Mundipharma’s CEO, said in the release. “The extended licensing footprint will provide physicians in the additional countries with more preservative-free treatment options for glaucoma patients.”

Mundipharma has expanded a partnership with Santen Pharmaceutical, according to a press release.

The extension of an existing license for Saflutan (tafluprost) will add approximately 50 Middle Eastern and African markets.

In addition, the company will add Taptiqom (tafluprost/timolol) to its license in Canada, Australia, New Zealand, Latin America, the Middle East and Africa.

“We are delighted to further expand our ophthalmic portfolio as well as our successful partnership with Santen, ” Raman Singh, Mundipharma’s CEO, said in the release. “The extended licensing footprint will provide physicians in the additional countries with more preservative-free treatment options for glaucoma patients.”